Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a platform study of ABBV142 in idiopathic pulmonary fibrosis
PACTR202605765630533Phase 2Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ABBV-142 in idiopathic pulmonary fibrosis (IPF), sponsored by AbbVie Inc. Planned start May 2026; status: not yet recruiting.
02
Drugs
ABBV-142
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on PACTR202605765630533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605765630533.